We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Regulator of the Necroptosis Cell Death Pathway Identified

By Biotechdaily staff writers
Posted on 28 Apr 2008
Researchers have found that three small molecules, necrostain-1, -3, and –5 inhibit the activity of the enzyme RIP1 kinase and prevent it from triggering the necroptosis cell death pathway.

Cells are programmed to die when they reach the end of their lifecycle, and that regulated process is called apoptosis. More...
Cells can also be killed through pathways not controlled by apoptosis. Until recently, this type of cell death, termed necrosis, was believed to be unregulated, a type of accidental cell death caused when cells are placed under extreme stress such as during a heart attack, stroke, or organ failure. Recent studies have shown, however, that necrotic cell death (necroptosis) is regulated and has a specific biochemical pathway.

Investigators at Tufts University (Boston, MA, USA) had previously found that three small molecules, necrostatin-1, necrostatin-3, and necrostatin-5 were inhibitors of the necroptosis pathway. The purpose of the current study was to identify the molecular target for necrostatin activity.

The investigators decided to focus on the enzyme RIP1 kinase because it had been previously reported by other groups to be important for necroptosis, and necrostatin-1 looked similar to known kinase inhibitors. Results obtained from in vitro enzyme interaction studies were published in the April 13, 2008, online edition of the journal Nature Chemical Biology.

"Our research found that RIP1 kinase can be inhibited by three small molecules: necrostatin-1, -3 and -5,” said first author Dr. Alexei Degterev, assistant professor of medicine at Tufts University. "Overall, these data establish RIP1 kinase as a new target for therapeutic drug development for human diseases involving necrotic tissue injury, and they establish necrostatins as first-in-class potent and selective inhibitors of RIP1 kinase. Next, research needs to determine the cellular pathway initiated by RIP1 kinase activity, develop better tools to further investigate its role in human disease, and establish how necrostatins are able to prevent RIP1 kinase from signaling the cell to kill itself. This may one day result in effective therapies, currently not available, for many life-threatening diseases.”


Related Links:
Tufts University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Prefilled Tubes
Prefilled 5.0ml Tubes
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Nian Sun has spent years perfecting a device that he believes could change the way diseases are detected. (Photo courtesy of Alyssa Stone/Northeastern University)

Rapid Breath Sensor Detects SARS-CoV-2 from Exhaled Air

Nasal swabs and polymerase chain reaction (PCR) testing have been central to identifying SARS-CoV-2, but they can be uncomfortable, slow, and logistically complex when samples require transport.... Read more

Molecular Diagnostics

view channel
Image: At the MHH Institute of Human Genetics: Prof. Dr. Doris Steinemann, Dr. Bernardus Aldrige Allister and Prof. Dr Monika Golas (from left). (Image Credit: Karin Kaiser/MHH)

Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer

Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.